Literature DB >> 9852250

Soluble fractions of tumor necrosis factor-alpha, interleukin-6 and of their receptors in toxic epidermal necrolysis: a comparison with second-degree burns.

P Paquet1, G E Piérard.   

Abstract

Drug-induced toxic epidermal necrolysis (TEN) is a rare bullous disease characterized by severe epidermal necrosis and sloughing. Soluble TNF-alpha(sTNF-alpha), soluble IL-6 (sIL-6) and their reactive soluble receptors (sTNF-Rp55 or-R1, sTNF-Rp75 or-R2, sIL-6R) were quantified in blister fluid and serum of 6 TEN patients and 13 cases of second-degree burn. The amounts of sTNF-alpha, sTNF-R1 and sTNF-R2 were significantly higher in TEN blisters than in burns reflecting the probable involvement of the TNF-alpha system in the specific pathomechanism of TEN. The ratio sTNF-alpha/sTNF-R2 was significantly lower in TEN blisters than in burns. The concentrations of sTNF-R2 in TEN blisters and serums were significantly greater than those of sTNF-R1. This suggests a potential important role for sTNF-R2 in TEN by enhancing the cytotoxic effect of TNF-alpha. In addition, both sTNF-R1 and sTNF-R2 were significantly more abundant in TEN blisters than in serums, indicating that the TNF-alpha processing was mainly a local event in the TEN skin. No significant difference could be established for sIL-6 and sIL-6R between TEN and burns. Although a role for IL-6 cannot be ruled out, its production has no specific characteristics in TEN compared to burns.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9852250     DOI: 10.3892/ijmm.1.2.459

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  4 in total

Review 1.  Skin manifestations of drug allergy.

Authors:  Michael R Ardern-Jones; Peter S Friedmann
Journal:  Br J Clin Pharmacol       Date:  2011-05       Impact factor: 4.335

2.  New insights in toxic epidermal necrolysis (Lyell's syndrome): clinical considerations, pathobiology and targeted treatments revisited.

Authors:  Philippe Paquet; Gérald E Piérard
Journal:  Drug Saf       Date:  2010-03-01       Impact factor: 5.606

3.  Fibroblasts protect melanoma cells from the cytotoxic effects of doxorubicin.

Authors:  Manoela Tiago; Edson Mendes de Oliveira; Carla Abdo Brohem; Paula Comune Pennacchi; Rafael Duarte Paes; Raquel Brandão Haga; Ana Campa; Silvia Berlanga de Moraes Barros; Keiran S Smalley; Silvya Stuchi Maria-Engler
Journal:  Tissue Eng Part A       Date:  2014-03-25       Impact factor: 3.845

Review 4.  Mechanisms of Severe Cutaneous Adverse Reactions: Recent Advances.

Authors:  Teresa Bellón
Journal:  Drug Saf       Date:  2019-08       Impact factor: 5.228

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.